<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531089</url>
  </required_header>
  <id_info>
    <org_study_id>CAG-1</org_study_id>
    <nct_id>NCT00531089</nct_id>
  </id_info>
  <brief_title>Rituximab in Patients With Relapsed or Refractory TTP-HUS</brief_title>
  <official_title>A Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients With Relapsed/Refractory Thrombotic Thrombocytopenic Purpura (TTP) - Hemolytic Uremic Syndrome (HUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Apheresis Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general objective of this study is to assess the efficacy and safety of Rituximab in the
      management of patients with refractory or relapsed thrombotic thrombocytopenic
      purpura-hemolytic uremic syndrome (TTP-HUS). There have been several case reports and case
      series describing the use of Rituximab in patients with TTP-HUS; however its use has not been
      studied in a large trial. It is hypothesized that Rituximab may ameliorate the severity of
      certain cases of TTP-HUS by decreasing the number of activity of B-cells which may result in
      decreased production of the ADAMTS13 protease inhibitor. Patients with TTP-HUS not responding
      to standard therapy or patients with relapsed disease may have particular benefit. Treatments
      that decrease the frequency of relapse or shorten the time to remission of TTP-HUS will be of
      benefit by decreasing the need for blood product support.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients achieving all: (1) platelet count &gt;150x109/L; (2) LDH &lt; 1.5 x normal; (3) no requirement for plasma exchange therapy; (4) asymptomatic.</measure>
    <time_frame>8 weeks after initiation of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with platelet count greater than 150 x 109/L</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with LDH &lt; 1.5 X normal</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with no requirement for plasma exchange therapy</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients who are asymptomatic (no new neurological symptoms ans stabilization of previous neurological symptoms</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical response (CR, PR, non-response)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of relapse</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in platelet counts, LDH, ADAMTS13 protease level, ADAMTS13 inhibitor level</measure>
    <time_frame>8, 12, 24, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity and clinical safety as assessed by monitoring of adverse events, laboratory parameters, vital signs during infusion, and immediate tolerability</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Thrombotic Thrombocytopenic Purpura</condition>
  <condition>Hemolytic Uremic Syndrome</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in the study will be in the study group and will receive rituximab. There is no &quot;control&quot; arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab will be administered on weeks 1, 2, 3, and 4 at a dose of 375 mg/m2 per infusion. Premedications (prednisone 50 mg, diphenhydramine 50 mg, acetaminophen) will be administered prior to study infusion. Patients will also be treated with plasma exchange as per institution/apheresis centre.</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Rituxan, rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any patient 18 years or older diagnosed with relapsed or refractory TTP-HUS requiring
             therapy

        Exclusion Criteria:

          -  alternate cause of hemolytic microangiopathy (evidence of DIC, malignant hypertension,
             vasculitis, anti-phospholipid antibody syndrome, post-partum acute renal failure)

          -  congenital or familial TTP

          -  TTP occuring post-stem cell, bone marrow, or solid organ transplant

          -  drug-induced TTP

          -  pregnancy or breast-feeding

          -  history of hepatitis B or C infection

          -  prior rituximab treatment

          -  active or metastatic cancer

          -  other causes of thrombocytopenia such as ITP, myelodysplastic syndrome, confirmed or
             suspected drug-induced thrombocytopenia

          -  refusal to receive blood products

          -  hypersensitivity to blood products, plasma products, murine proteins, or any component
             of the Rituximab formulation

          -  geographic inaccessibility

          -  co-morbid illness limiting life expectancy to less than 2 months independent of TTP

          -  failure to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn E Webert, E</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronan Foley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gail Rock, MD</last_name>
    <role>Study Director</role>
    <affiliation>Canadian Apheresis Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Clark, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Western Ontario/London Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Barth, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathryn E Webert, MD</last_name>
    <phone>905-521-2100</phone>
    <phone_ext>76733</phone_ext>
    <email>webertk@mcmaster.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Foothills Medical Centre, Calgary Health REgion Apheresis Service</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Klassen, MD</last_name>
      <phone>403-944-4712</phone>
      <email>john.klassen@calgaryhealthregion.ca</email>
    </contact>
    <investigator>
      <last_name>John Klassen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>L Larratt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Yenson, Dr.</last_name>
      <phone>604-875-4863</phone>
      <email>pyenson@bccancer.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Basque</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>69014</phone_ext>
      <email>lbasque@bccancer.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Yenson, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winnipeg Regional Health Authority, Apheresis Department</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cathy Moltzan, MD</last_name>
      <phone>204-787-4269</phone>
      <email>cmoltzan@sbgh.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Cathy Moltzan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John Regional Hospital</name>
      <address>
        <city>St. John</city>
        <state>New Brunswick</state>
        <zip>E2K5S9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sean Dolan, MD</last_name>
      <phone>506-634-1201</phone>
    </contact>
    <investigator>
      <last_name>Sean Dolan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Carruthers</last_name>
      <phone>905-525-9140</phone>
      <phone_ext>22942</phone_ext>
      <email>carrutj@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Kathryn E Webert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronan Roley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donald M Arnold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre, Westminister Campus</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clark F William, MD</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>57238</phone_ext>
      <email>william.clark@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>William F Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital, ABMT/Apheresis Unit</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Barth, MD</last_name>
      <phone>416-946-4688</phone>
      <email>david.barth@uhn.on.ca</email>
    </contact>
    <investigator>
      <last_name>David Barth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Lemoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S Fox, MD</last_name>
      <phone>450-466-5000</phone>
    </contact>
    <investigator>
      <last_name>S Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J P Moquin, MD</last_name>
      <phone>514-338-2222</phone>
      <phone_ext>3368</phone_ext>
      <email>jp.moquin@videotron.ca</email>
    </contact>
    <investigator>
      <last_name>J P Moquin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital Apheresis Unit</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7M 0Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Shoker, MD</last_name>
      <phone>306-655-5934</phone>
      <email>ahmed.shoker@usask.ca</email>
    </contact>
    <investigator>
      <last_name>Ahmed Shoker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2007</study_first_submitted>
  <study_first_submitted_qc>September 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2007</study_first_posted>
  <last_update_submitted>May 18, 2010</last_update_submitted>
  <last_update_submitted_qc>May 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Canadian Apheresis Group</name_title>
    <organization>Canadian Apheresis Group</organization>
  </responsible_party>
  <keyword>TTP</keyword>
  <keyword>thrombotic thrombocytopenic purpura</keyword>
  <keyword>HUS</keyword>
  <keyword>hemolytic uremic syndrome</keyword>
  <keyword>plasma exchange</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Azotemia</mesh_term>
    <mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
    <mesh_term>Purpura, Thrombotic Thrombocytopenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

